Mitchell Ho

9.1k total citations · 2 hit papers
142 papers, 6.5k citations indexed

About

Mitchell Ho is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Mitchell Ho has authored 142 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 59 papers in Radiology, Nuclear Medicine and Imaging and 55 papers in Immunology. Recurrent topics in Mitchell Ho's work include Monoclonal and Polyclonal Antibodies Research (58 papers), CAR-T cell therapy research (49 papers) and Glycosylation and Glycoproteins Research (29 papers). Mitchell Ho is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (58 papers), CAR-T cell therapy research (49 papers) and Glycosylation and Glycoproteins Research (29 papers). Mitchell Ho collaborates with scholars based in United States, China and United Kingdom. Mitchell Ho's co-authors include Ira Pastan, Raffit Hassan, Wei Gao, Heungnam Kim, Mingqian Feng, Yu‐suke Torisawa, Shuichi Takayama, Steven G. Allen, Yi‐Chung Tung and Amy Y. Hsiao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Mitchell Ho

133 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array

2010 759 citations Yi‐Chung Tung, Amy Y. Hsiao et al. The Analyst profile →
Cancer therapy with antibodies

2024 102 citations Mitchell Ho et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell Ho United States	47	2.6k	2.1k	1.7k	1.4k	1.1k	142	6.5k
Paule Opolon France	44	3.5k 1.3×	1.5k 0.7×	1.1k 0.7×	564 0.4×	696 0.6×	159	6.6k
Olivier Gires Germany	42	2.8k 1.1×	3.4k 1.6×	1.3k 0.8×	462 0.3×	448 0.4×	109	6.2k
Tetsuya Nakatsura Japan	37	2.3k 0.9×	2.1k 1.0×	1.8k 1.1×	402 0.3×	575 0.5×	139	5.0k
Hayao Nakanishi Japan	42	2.3k 0.9×	1.7k 0.8×	792 0.5×	538 0.4×	327 0.3×	177	5.8k
Esther H. Chang United States	51	5.9k 2.3×	3.1k 1.5×	1.1k 0.6×	698 0.5×	893 0.8×	124	9.6k
Mark Selby United States	42	3.0k 1.2×	3.4k 1.6×	3.2k 1.9×	818 0.6×	209 0.2×	96	9.6k
Edith M. Lord United States	41	1.8k 0.7×	2.2k 1.0×	2.5k 1.5×	990 0.7×	503 0.4×	139	6.1k
Gerhard Moldenhauer Germany	52	3.4k 1.3×	2.7k 1.2×	2.9k 1.7×	1.8k 1.3×	268 0.2×	129	7.6k
Jennifer R. Cochran United States	46	3.3k 1.3×	1.3k 0.6×	1.3k 0.8×	2.1k 1.5×	1.1k 0.9×	111	6.3k
Neil Senzer United States	43	3.6k 1.4×	3.9k 1.8×	1.2k 0.8×	267 0.2×	477 0.4×	176	7.8k

Countries citing papers authored by Mitchell Ho

Since Specialization

Citations

This map shows the geographic impact of Mitchell Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Ho more than expected).

Fields of papers citing papers by Mitchell Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Ho. The network helps show where Mitchell Ho may publish in the future.

Co-authorship network of co-authors of Mitchell Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Ho. A scholar is included among the top collaborators of Mitchell Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell Ho. Mitchell Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hong, Jessica, et al.. (2026). Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma. Hepatology Communications. 10(2).

Okada, Reona, Taisuke Kondo, Jangsuk Oh, et al.. (2025). GPC2-Targeted CAR T Cells Engineered with NFAT-Inducible Membrane-Tethered IL15/IL21 Exhibit Enhanced Activity against Neuroblastoma. Cancer Immunology Research. 13(9). 1363–1373. 1 indexed citations

Yu, Yanlin & Mitchell Ho. (2025). CAR NK cell therapy for solid tumors: potential and challenges. PubMed. 8(4). 275–289.

Li, Dan, T. Jake Liang, Laura Hutchins, et al.. (2024). rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. Journal for ImmunoTherapy of Cancer. 12(7). e008989–e008989. 14 indexed citations

Li, Dan, et al.. (2024). Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma. American Journal Of Pathology. 195(3). 453–469. 3 indexed citations

Cao, Yingying, Reona Okada, Haiying Qin, et al.. (2023). Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma. Journal for ImmunoTherapy of Cancer. 11(1). e005881–e005881. 18 indexed citations

Stathopoulou, Chaido, Jessica Hong, Mitchell Ho, & Raffit Hassan. (2023). Abstract 1786: Mesothelin-targeting, nanobody-based CAR T cells effectively target solid tumors in fully immunocompetent hosts. Cancer Research. 83(7_Supplement). 1786–1786. 1 indexed citations

Nguyen, Rosa, Ekaterina Doubrovina, Reona Okada, et al.. (2023). Cooperative Armoring of CAR and TCR T Cells by T Cell–Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy. Clinical Cancer Research. 30(8). 1555–1566. 23 indexed citations

Hong, Jessica, Hyung Joon Kwon, Raúl E. Cachau, et al.. (2022). Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. Proceedings of the National Academy of Sciences. 119(18). 27 indexed citations

10.

Tomar, Sakshi, Jingli Zhang, Manakamana Khanal, et al.. (2022). Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Molecular Cancer Therapeutics. 21(7). 1195–1206. 31 indexed citations

11.

Pan, Jiajia, Nan Li, Alex Renn, et al.. (2022). GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular Cancer Therapeutics. 21(6). 960–973. 8 indexed citations

12.

Swenson, Rolf E., Ying Fu, Jessica Hong, et al.. (2019). In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. Cancer Biotherapy and Radiopharmaceuticals. 34(8). 498–503. 9 indexed citations

13.

Li, Dan, Nan Li, Yifan Zhang, et al.. (2018). Development of CAR T cell therapy targeting glypican-3 in liver cancer. Cancer Biology and Medicine. 15. 17. 1 indexed citations

14.

Gao, Wei, Yongmei Xu, Jian Liu, & Mitchell Ho. (2016). Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Scientific Reports. 6(1). 26245–26245. 48 indexed citations

15.

Gao, Wei, Heungnam Kim, & Mitchell Ho. (2015). Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells. PLoS ONE. 10(9). e0137664–e0137664. 65 indexed citations

16.

Tang, Zhewei, Mingqian Feng, Wei Gao, et al.. (2013). A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface. Molecular Cancer Therapeutics. 12(4). 416–426. 38 indexed citations

17.

Onda, Masanori, et al.. (2011). The improvement of an anti-CD22 immunotoxin. mAbs. 3(5). 479–486. 12 indexed citations

18.

Torisawa, Yu‐suke, Bobak Mosadegh, Stephen P. Cavnar, Mitchell Ho, & Shuichi Takayama. (2010). Transwells with Microstamped Membranes Produce Micropatterned Two-Dimensional and Three-Dimensional Co-Cultures. Tissue Engineering Part C Methods. 17(1). 61–67. 18 indexed citations

19.

Zhang, Yujian, Johanna K. Hansen, Laiman Xiang, et al.. (2010). A Flow Cytometry Method to Quantitate Internalized Immunotoxins Shows that Taxol Synergistically Increases Cellular Immunotoxins Uptake. Cancer Research. 70(3). 1082–1089. 34 indexed citations

20.

Tung, Yi‐Chung, Amy Y. Hsiao, Steven G. Allen, et al.. (2010). High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. The Analyst. 136(3). 473–478. 759 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact